- Submission Deadline: Thursday, August 8
- Notification: Week of September 16
- Final Presentation PDF Due: January 6, 2025
- Forum Dates: January 27-29, 2025
- Location: Hilton Baltimore Inner Harbor, Baltimore, MD
- Questions: Contact Damisha.White@DIAGlobal.org
Call for Abstracts
Are you a professional involved in pharmacovigilance and risk management? If so, DIA wants to hear from YOU as we prepare for the DIA Global Pharmacovigilance and Risk Management Strategies Conference. This conference is a neutral event developed by regulators and industry experts discussing the updates, opportunities, and challenges alongside fresh problem-solving strategies that matter most to safety professionals.
To ensure that we have the most comprehensive and cutting-edge program, we are seeking abstract submissions from professionals like yourself, who are pushing the boundaries in their respective fields. We encourage you to submit abstracts that reflect the latest trends, innovations, and best practices in pharmacovigilance and risk management. We will be accepting the following formats:
- Presentations: 15-20 minute presentations to be bundled with other presentations to create a session
- Sessions: 75 minute total session
- Short Courses: Three-hour interactive workshop delivered in a small group format (require a separate fee from attendees)
The Program Committee is seeking abstracts on the following topics (keep in mind, business use cases and lessons learned are encouraged in all topic areas). Please note that topics in addition to those listed below, that you feel are relevant, may be submitted for evaluation and possible selection.
Interest Areas
- Aggregate Safety Assessment Plan (ASAP)
- ChaptGPT and its effect on Safety Professionals
- Clinical Trial Safety Evaluations
- Emerging Trends in Pharmacovigilance
- Epidemiology and Pharmacovigilance
- FDA’s standard tables and figures, and FMQs
- Future of the Pharmacovigilance Professional
- Good Pharmacovigilance Practices (GVP)
- Global Pharmacovigilance Updates from Regulatory Authorities
- GVP Inspections (In-Person and Virtual)
- ICH Safety Related Updates
- Implementation Strategies for Additional Risk Minimization Measures
- Literature Surveillance
- Patient Centricity in Pharmacovigilance
- Pharmacovigilance Perspectives from Startups and Small Pharmaceutical Companies
- Post-Approval Safety Studies
- Reference Safety Information (RSI) Use in Clinical Trials
- Risk Communication
- Risk Evaluation and Mitigation Strategy (REMS)
- Risk Management Plan (RMP)
- Risk Management Strategies
- Safety and Pharmacovigilance for Advanced Therapies
- Safety Governance Models
- Safety for Special Populations (e.g., children, pregnant women, etc.)
- Safety for Biosimilars and Generics
- Safety for Combination Products, Diagnostics, and Medical Devices
- Signal Detection
- Strategies to Effectively Adopt Innovation
- Use of Artificial Intelligence (AI), Machine Learning (ML), Automation, and Technology in Pharmacovigilance
- Other
Submission Guidelines
To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your abstract as early as possible. Do not wait until the last day.
Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. All of the below fields are required.
- Author Information
- Abstract Information
- Abstract Title: (125 characters including spaces)
- Interest Area: Choose from the drop down
- Keywords: Provide one or more keywords to highlight your abstract. Examples of keywords: Personalized Medicine, Health Technology Assessment, etc. (100 characters)
- Level of Difficulty: Beginner, Intermediate, or Advanced
- Learning Objectives: Provide 2-3 learning objectives that clearly explain what participants should be able to do after attending this event. For a list of suggested verbs to create these objectives, click here. (400 Characters)
- Overview: *Please provide 2-3 sentences summarizing your abstract. This summary will be used as the overview description in the DIA program for marketing purposes (250 Characters including spaces)
- Abstract Details: *Please provide complete details about your abstract. Information such as scientific, technical, process issues, design/methods, results/outcomes, case studies, statistics, key findings, etc., that would support your proposal should be included here. This information will be used by the Program Committee to learn more about the purpose of your abstract. Is there an interactive component to your topic? If so, please indicate in the abstract details how you would be able to include an interactive learning experience for attendees. (2000 Characters including spaces)
We ask that all abstracts be noncommercial and not appear as a marketing opportunity. Submitters must adhere to DIA’s Policy Concerning Promotion of Products and Services from the Podium.
